Fullerene C 60 has great potential for use in many industry and medical nanotechnology applications. Although the use of nanomaterials has been increasing in the recent years, limited information about its potential hazardous effects is available. Therefore, safety of nanomaterials is a world concern. Before health effects arise in workers and the general population, development and use under appropriate management are desirable. Therefore, we aimed to determine an acceptable exposure level for humans by reviewing the limited animal toxicity data available. Here, we present an initial hazard assessment, including a review of the available toxicity information of the effects of C 60 on the lungs. We then estimated the no-observed-adverse-effect level (NOAEL) of C 60 on rat lung toxicity by using lung retention of C 60 in inhalation exposure and intratracheal instillation tests. The NOAEL of C 60 on rat lung toxicity was estimated to be 3.1 mg/m 3 . Because this is the NOAEL for subchronic toxicity, a periodlimited acceptable exposure level (AEL(PL)) for humans was proposed, which assumed 15 years of exposure and modification within the next 10 years since more knowledge will be gained in the future. The AEL(PL) of C 60 particles with a geometric mean of 96 nm and a geometric standard deviation (GSD) of 2.0 was estimated to be 0.39 mg/m 3 for healthy workers and 1.4 3 10 22 mg/ m 3 for the general human population. The AEL(PL) of C 60 particles with different sizes was estimated to be 0:393 0:0913 fwork;d¼x;GSD5y mg/m 3 for healthy workers and 0:014 3 0:107 fenv;d¼x;GSD5y mg/m 3 for the general human population.
Fullerene C 60 , which was developed in 1985 (Kroto et al., 1985) and possesses unique physical and chemical properties, has potential for use in many industry and medical nanotechnology applications, including energy conversion and drug delivery. There has been worldwide concern about the safety of nanomaterials due to the lack of information available regarding their potential hazardous effects. An exposure guideline value such as the acceptable exposure level is needed as soon as possible to protect workers and the general population.
Since 2008, a Japanese panel on engineered nanomaterials has been organized by the Ministry of Economy, Trade, and Industry; Ministry of Health, Labor, and Welfare; and Ministry of the Environment. In Japan, a research project entitled ''Evaluating risks associated with manufactured nanomaterials'' has been in progress for the past 5 years (starting in 2006) with the support of New Energy and Industrial Technology Development Organization.
Meanwhile, the U.S. Environmental Protection Agency (EPA) has collected information about nanoscale materials through the Nanoscale Materials Stewardship Program since 2008. Under the Toxic Substances Control Act, the EPA requires notification 90 days before the production or import of C 60 . In addition, the EPA is considering a requirement of 90-day inhalation exposure testing and 90-day observation of carbon nanoscale materials. Since 2005, the U.S. National Institute for Occupational Safety and Health (NIOSH) has frequently revised its document ''Approaches to safe nanotechnology: Managing the health and safety concerns associated with engineered nanomaterials'' (NIOSH, 2009 ). However, the toxicity could not be determined in an inhalation exposure test in many cases because inhalation exposure tests are difficult to conduct at high concentrations (due to the difficulties in generating stabile particle concentrations).
The European Commission (EC) Joint Research Centre's Institute for Health and Consumer Protection published in 2008 a list of Pre-Registered Substances, including fullerenes, multiwalled carbon nanotubes, single-walled carbon nanotubes, and other nanomaterials. The production, use, exposure, toxicity, environmental toxicity, epidemiology, and risk assessment for these materials were presented in a study entitled ''Engineered nanoparticles-Review of health and environmental safety'' (ENRHES) (EC, 2010) . In that document, the derived noeffect levels (DNELs) of C 60 for workers were calculated to be 4.44 3 10 À2 mg/m 3 and 2.7 3 10 À4 mg/m 3 for acute and chronic exposure, respectively. The DNEL for chronic exposure was based on the gene expression study by Fujita et al. (2009) , although gene expression can indicate the mechanism and potential for adverse effects but not the actual adverse effect.
Here, we have presented a hazard assessment, including a review of the available toxicity information on the effects of C 60 on lungs. We then estimated the no-observed-adverse-effect level (NOAEL) of C 60 on lung toxicity based on lung retention of C 60 in an inhalation exposure test and an intratracheal instillation test. Finally, we proposed a period-limited acceptable exposure level (AEL(PL)), which assumed that the worker would be exposed to C 60 particles for 15 years and should be modified within the next 10 years as new knowledge becomes available.
MATERIALS AND METHODS
First, previous toxicity studies associated with C 60 , which included lung retention, disposition (Table 1) , and the results of inhalation exposure tests (Table 2 ) and intratracheal instillation tests (Table 3) , were reviewed. The endpoint in this assessment was decided according to the results of the review.
Next, the NOAEL on rat lung was estimated based on the results of the review. In the estimation, we assumed that the intratracheal instillation test is equivalent to the inhalation exposure test when the maximum lung retention in the intratracheal instillation test is equal to the maximum lung retention in the 90-day inhalation exposure test. The lung retention was calculated using the following equations:
where A (mg per lung) and I (mg per lung) are the retentions of C 60 in lung compartments 1 and 2, respectively; C (mg/m 3 ) is the exposure concentration of C 60 ; V (m 3 /min) is the respiratory volume; f (dimensionless) is the alveolar deposition fraction; and k 1 , k 12 , and k 2 (per day) are the clearance rate constants for rapid clearance, translocation from compartment 1 to 2, and slow clearance, respectively.
Subsequently, NOAELs were estimated for workers and the general human population with corrections for exposure period, respiratory volume, and deposition fraction. Finally, acceptable exposure levels for workers and for humans in the general environment were obtained by dividing the human NOAEL by uncertainty factors using the following equation:
Hazard Assessment
Kinetics information regarding C 60 after inhalation exposure. The percentage of airborne C 60 nanoparticles deposited in the lungs' alveolar region is known as the deposition mass fraction and can be calculated by using models such as the Multiple-Path Particle Dosimetry (MPPD) model (National Institute for Public Health and the Environment [RIVM], 2002) (Fig. 1) . The deposition mass fractions for rats and humans are 0.17 and 0.19, respectively, for a particle with a diameter of 100 nm whose density is 1.2 g/cm 3 . For smaller particles, the deposition mass fraction for humans is higher than that for rats. Previous experimental results have reported the deposition mass fractions of the C 60 particle for rats as 0.14 and 0.18 for particles with a count-based average geometric-mean (GM) diameter of 96 nm (geometric standard deviation [GSD], 2.0) and a count-median diameter of 55 nm (GSD, 1.48), respectively (Shinohara et al., 2010) .
Regarding C 60 retention in the lungs, the half-life of inhaled or intratracheally instilled C 60 in rat lung has been reported as 26 and 29 days (median diameters, 55 and 930 nm; doses, 2.22 and 2.35 mg/m 3 ; Baker et al., 2008) , 14 and 22 days (GM diameters:~20 and 1000 nm; doses, 1.0 mg/kg and 1 mg/m 3 ; Gao et al., 2009) , and 15-28 days (GM diameter: 35 nm; dose: 0.1-1.0 mg per rat; Shinohara et al., 2010) . After the deposition, C 60 can be cleared from lung by rapid and slow clearance pathways (clearance rate constants k 1 , k 12 , k 2 : 0.029-0.047, 0.00044-0.0034, and 0-0.0042 per day, respectively) (Shinohara et al., 2010) . Rapid clearance would be attributable to phagocytosis by alveolar macrophages, transfer to the tracheobronchial region, and elimination in the sputum. Slow clearance would be attributable to elimination through the lymph nodes.
In some reports, C 60 particles were detected in the liver and spleen after intraperitoneal or intravenous injection, but there are no reports of the translocation of C 60 particles to the brain (Bullard-Dillard et al., 1996; Gharbi et al., 2005; Moussa et al., 1996) . Clearance of C 60 from the blood after an intravenous injection was extremely fast, taking place within 1 min, and most of the cleared C 60 accumulated in the liver, where it remained for over 120 h (Bullard-Dillard et al., 1996) . Thus, it is confirmed that C 60 does not translocate from the lungs to the other organs via the blood because C 60 was not detected in the liver (< 2.0 3 10 À4 mg per liver) at 1-180 days after intratracheal instillation (1.0 mg per rat) or at 3-30 days after inhalation exposure (0.12 mg/m 3 ) (Shinohara et al., 2010) . In addition, C 60 was not detected in the brain (< 2.0 3 10 À5 mg per brain) at 1-180 days after intratracheal instillation (1.0 mg per rat) or at 3-30 days after inhalation exposure (0.12 mg/m 3 ) (Shinohara et al., 2010) . Therefore, it can be concluded that C 60 does not translocate from lung to brain via the olfactory bulb, although ultrafine carbon particles could be translocated to the brain via the olfactory bulb (3.5 3 10 À4 -4.3 3 10 À4 mg/g) after inhalation exposure (0.16 mg/m 3 ) (Oberdörster et al., 2004) .
Because translocation of fullerene particles to organs other than the lungs after inhalation exposure has not been reported, it is considered sufficient to use the adverse effects in the lungs as the critical endpoint for risk assessment.
Toxicity of C 60 in the lungs -inhalation exposure test. Previous studies examined alveolar inflammation as a possible adverse effect of inhalation exposure to C 60 particles. Direct observation of inflammation, total and neutrophilic cell counts in bronchoalveolar lavage fluid (BALF), and cytokine amounts in BALF have been used as indicators of alveolar inflammation.
In an inhalation study, Baker et al. (2008) performed pulmonary toxicity assessments on rats for a 7-day observation period after 10 days of inhalation exposure (3 h/day) to nanosized (count-median diameter, 55 nm; concentration, 2.22 mg/m 3 ) C 60 particles prepared by ball-milling, sublimation, and agglomeration and to micron-sized (count-median diameter, 930 nm; concentration, 2.35 mg/m 3 ) C 60 particles prepared by ball-milling. For the nanosized C 60 fullerenes, there were no significant differences in BALF cytokines in rats. Although a rise in BALF protein concentration was noted, this could not be considered as an adverse effect because a slight increase in protein concentration does not directly indicate a toxic effect. In this report, nanoscale and microscale fullerenes induced only minimal toxicity in a short-term exposure test. Yokoyama et al. (2009) subjected ICR mice to an inhalation test of an aerosol of C 60 (count-based GM diameter, 86 nm; concentration, 1.6 3 10 5 particles/cm 3 ). The measurement of the electron paramagnetic resonance at 700 MHz confirmed the suppression of the reducing ability of the nickel oxide nanoparticles used as a positive control but not that of the C 60 . Thus, C 60 does not induce acute effects on the lungs in terms of reducing ability.
Furthermore, Morimoto et al. (2010) exposed Wistar rats to 0.12 mg/m 3 of C 60 aerosol (count-based GM diameter, 96 nm; concentration, 4.1 3 10 4 particles/cm 3 ) for 6 h/day, 5 days/week for 4 weeks, followed by 3 months C 60 HAZARD ASSESSMENT Toxicity of C 60 in the lungs -intratracheal instillation test. Sayes et al. (2007) reported on single intratracheal instillations of C 60 suspensions (160 ± 50 nm diameter) at levels of 0.2, 0.4, 1.5, and 3.0 mg/kg (0.05, 0.09, 0.35, and 0.7 mg per rat) to rats (average weight, 230 g). Increased neutrophil numbers in the BALF and significant marked inflammation were observed at 24 h after administration of C 60 , but the responses were not persistent. Significant increases in lipid peroxidation in the BALF were observed at 24 h and 3 months after C 60 administration at doses of 0.35 and 0.7 mg per rat. The authors concluded that no adverse lung tissue effects were induced by the highest dose of C 60 for up to 3 months because persistent inflammation was not observed at 1 week, 1 month, and 3 months after the instillation. Jacobsen et al. (2009) conducted an intratracheal instillation test of C 60 particles (volume-based mean diameter, 211 nm) at 5.4 3 10 À2 mg per mouse using apolipoprotein E-knockout mice. Levels of some cytokines (Mcp-1, for example) were significantly increased during the 24-h observation period after the instillation, but the increase due to C 60 was much smaller than that due to carbon nanotube or carbon black. Morimoto et al. (2010) reported the results of intratracheal instillation studies on Wistar rats using a stably dispersed C 60 suspension (median and 90th-percentile particle sizes based on volume, 33 and < 100 nm). Single intratracheal instillations of fullerenes at 0.1, 0.2, or 1.0 mg per rat (0.33, 0.66, or 3.3 mg/kg) were followed by 6 months of observation. At the highest dose (1.0 mg per rat), pulmonary inflammation primarily caused by neutrophils was observed in the BALF and lungs. Increased expression of HO-1 was also observed. However, both findings were transient or mild in severity. At the lower doses, pulmonary inflammation was not observed until 6 months after the instillation. Furthermore, at all doses, there were no findings of granuloma, fibrotic change, or emphysematous change. Park et al. (2010) conducted an intratracheal instillation of C 60 prepared using toluene in ICR mice (2 mg/kg, 0.05 mg per mouse) and reported an FIG. 1. Size-dependent particle deposition fractions on the alveolar surface of rat (left) and human (right) lungs. Calculated using the MPPD model ( 
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SHINOHARA, GAMO, AND NAKANISHI increase in the expression of some cytokines related to inflammation, such as proinflammatory cytokines and Th1 cytokines, in the BALF at 14 and 28 days after the instillation.
Calculations
Determination of the NOAEL of C 60 on rat lung toxicity based on the inhalation exposure test. In the Morimoto et al. (2010) study discussed above, adverse effects were not observed for 3 months after the 28-day inhalation exposure to a C 60 concentration of 0.12 mg/m 3 . However, the U.S. Toxic Substances Control Act plans to require the submission of the results of a 90-day inhalation exposure test in rats with a postexposure observation period of up to 3 months. Thus, we tried to estimate whether adverse effects would be induced within the 3-month observation period if the exposure to 0.12 mg/m 3 of C 60 in the Morimoto et al. (2010) study was extended to 90 days. In this calculation, we used the deposition mass fraction of 0.14 for inhaled C 60 reported in the Shinohara et al. (2010) 28-day inhalation test (0.12 mg/m 3 ) and the clearance rate constants k 1 , k 2 , and k 12 of 0.047, 0.0042, and 0.0028 /day, respectively, from the intratracheal instillation test (0.1 mg per rat) described by Shinohara et al. (2010) . The rat respiration rate was calculated with the equation in Bide et al. (2000) to be 0.27 m 3 /day for a 300 g rat.
Using these numbers, we calculated the lung retention after 90 days of exposure to be 0.0194 mg per lung (Fig. 2, left) . Because no adverse effects were observed after 3 months at much higher lung-retention levels of C 60 (such as 0.1, 0.2, and 0.7 mg per lung) in the results of intratracheal instillation tests, we argue that 90 days' exposure to 0.12 mg/m 3 of C 60 would not induce any adverse effects during a 3-month observation period. Because no adverse effects have been observed in any previous inhalation exposure tests on C 60 nanoparticles, the NOAEL of C 60 on rat lung toxicity (NOAEL rat ) could reasonably be set higher than 0.12 mg/m 3 . Thus, we decided to estimate the equivalent NOAEL of inhalation exposure according to the intratracheal instillation test.
Equivalent NOAEL of C 60 on rat lung toxicity based on the intratracheal instillation test. In Morimoto et al. (2010) , slight effects on the biomarkers associated with lung inflammation, such as the increase of neutrophils in the BALF, were observed at a dose of 1.0 mg/rat (3.3 mg/kg), whereas no adverse effects were observed at a dose of 0.7 mg per rat (3.0 mg/kg) in Sayes et al. (2007) . According to these studies, we decided to use 1.0 mg/rat (3.3 mg/kg) as the lowest-observe-adverse-effect level and 0.7 mg/rat (3.0 mg/kg) as the NOAEL on rat lung toxicity for the inhalation route.
Therefore, the NOAEL on rat lung for the 90-day inhalation exposure test was estimated from the NOAEL in the intratracheal instillation test (0.7 mg per lung). In this estimation, we assumed that the intratracheal instillation test is equivalent to the inhalation exposure test when the maximum lung retention (instillation amount) in the intratracheal instillation test is equal to the maximum lung retention in the 90-day inhalation exposure test (Fig. 2, right) . The clearance rate constants k 1 , k 2 , and k 12 in the intratracheal instillation test (1.0 mg per rat)-0.029, 0.0001, and 0.00044/day, respectively-and the deposition mass fraction-0.14-for C 60 particles with a GM diameter of 96 nm (GSD, 2.0) were derived from Shinohara et al. (2010) . The rat respiration rate was calculated with the equation in Bide (2002) as 0.27 m 3 /day for a 300 g rat.
Our calculation indicated that the exposure concentration is 3.1 mg/m 3 when the maximum lung retention at 90 days of exposure (6 h/day and 5 day/week) is 0.7 mg. Therefore, the equivalent NOAEL on rat lung in the 90-day inhalation exposure test (NOAEL rat ) is decided to be 3.1 mg/m 3 . For comparison, if 0.18 was used as the deposition mass fraction and 0.22 m 3 /day (230 g body weight) as the rat respiration rate (according to Sayes et al., 2007) , the equivalent NOAEL rat would be calculated as 2.9 mg/m 3 . If we assume that the intratracheal instillation test is equivalent to the inhalation exposure test when the area under the curve (AUC) over 90 days is the same in both tests, the NOAEL is calculated to be 1.2 mg/m 3 .
Determination of the NOAEL for humans. The NOAEL for human workers (NOAEL human_work ) and the NOAEL for general human population (NOAEL human_env ) for a C 60 particle with a GM diameter of 96 nm (GSD, 2.0) were derived using the equivalent NOAEL for rats (NOAEL rat ) by correcting for the exposure period and species difference as follows: where t (h/day) and day (days/week) are the exposure times in hours and days, f (dimensionless) is the deposition mass fraction in the lungs, q (m 3 /day) is the respiration rate, and BW (kg) is the body weight. The subscripts ''rat,'' ''human,'' ''human_work,'' and ''human_env'' indicate rats, humans, human workers, and humans with general environmental exposure, respectively. The parameters used in the calculation are shown in Table 4 .
The NOAEL human_work and NOAEL human_env of C 60 nanoparticles with a GM diameter of 96 nm (GSD, 2.0) were calculated to be 3.5 mg/m 3 and 1.3 mg/m 3 , respectively. In general, it is appropriate to consider the inhalation toxicity of a particle to be inversely proportional to the alveolar surface area because the toxicity is induced at the deposition site. However, there are few data about alveolar surface areas for each toxicity test although the alveolar surface areas differ according to the type and age of the rat. Therefore, body weight was used for the rat-to-human conversion because there is sufficient data about body weight of different strains and ages of rats. Estimation of the secondary-particle-size-dependent NOAEL. The NOAEL calculated above was derived for a C 60 particle with a GM diameter of 96 nm (GSD, 2.0). As previously mentioned, the deposition mass fraction in the pulmonary alveolus depends on the secondary particle size. Thus, the secondary-particle-size-dependent NOAELs, reflecting the differences in the deposition mass fraction, can be obtained with the following equations: The concept of period-limited acceptable exposure level. There is little information available concerning the toxicity of nanoparticles, although the number of reports on the toxicology of nanoparticles has been increasing recently. The use of nanomaterials has also been increasing in the recent years. In this situation, an exposure guideline value such as an acceptable exposure level is required as soon as possible. However, as mentioned above, the NOAEL for the lung for chronic exposure to C 60 could not be obtained, but the NOAEL for the lung for subchronic exposure could be obtained based on the rat 90-day inhalation exposure test. The Deutsche Forschungsgemeinschaft (DFG) proposed that the Maximal Arbeitplatz-Konzentration (maximum workplace concentration) (MAK) for chronic exposure can be obtained by dividing the human NOAEL in the 13-week exposure test by 2 (DFG, 2009) . In this study, however, we consider that the acceptable exposure level must be period limited because the result of the 90-day exposure test can be used only for subchronic exposure. We propose that the limited period should be 15 years, which is the result obtained by dividing the working years (30-45 years) by 2 or 3. In addition, the AEL(PL) should be modified within 10 years because new knowledge will be available in the future.
Uncertainty factors. To derive the AEL(PL), which assumes that workers will receive 15 years' exposure and should be modified within the next 10 years as new knowledge becomes available, we considered several uncertainty factors.
Species differences in kinetics and sensitivity to adverse effects of xenobiotics are expressed with toxicokinetics and toxicodynamics. Regarding toxicokinetics, the uncertainty factor between rats and humans was set as 1 because the adverse effects related to the pulmonary inflammation-the critical endpoint in this risk assessment-are local and depend only on the alveolar deposition mass fraction of the particles. Regarding toxicodynamics, which is related to the species differences in sensitivity to toxicity induction, the uncertainty factor for chemical substances has been proposed as 1-3 by the U.S. EPA (2002) and as 2.5 by the EC (European Chemicals Agency [ECHA]). Because it has been suggested that rats have greater sensitivity to particle exposures than do humans (Borm et al., 2006) , the uncertainty factor for toxicodynamics was set as 1 in this assessment.
For extrapolation of the exposure period from a subchronic exposure test (90 days) to a chronic effect (2 years) on the respiratory system due to particulate matter, the uncertainty factor of 1 (ECHA, 2008) or 2 (European Centre for Ecotoxicology and Toxicology of Chemicals [ECETOC], 2010) was used. In the present assessment, the AEL(PL) was considered to be subchronic (15-year exposure) according to the subchronic results (90-day exposure test). Therefore, the exposure period extrapolation was considered to be 1.
Here, we extrapolated from the results of the intratracheal instillation test (instillation and 90-day observation) performed by Sayes et al. (2007) , instead of the 90-day inhalation exposure test involving the use of lung retention and clearance data performed by Shinohara et al. (2010) (instillation and 180-day observation). If we assume that the intratracheal instillation test is equivalent to the inhalation exposure test when the AUC is the same in both tests over 90 days, the NOAEL is reduced to one-third of the value calculated using this assessment. Based on these points, we determined the uncertainty factor for the extrapolation to be 3 in this assessment.
In the conversion of the NOAEL for rats to the NOAEL for humans, we assumed that the strength of toxicity was same when the deposition rate (concentration) was same between rats and humans. This conversion is not necessarily conservative compared with a conversion using alveolar retention. Thus, the uncertainty factor for the interspecies conversion of NOAEL was set as 3 in this assessment.
For individual differences among humans, the uncertainty factor is considered to be 1, given that the workers in the occupational environment are healthy and, thus, not considered to be a sensitive population. The uncertainty factor for the individual differences of hazard sensitivity among humans in the general environment is considered to be 10.
The total uncertainty factor of the NOAEL human_work for the occupational environment was calculated to be 9 by multiplying the above uncertainty factors. When this is multiplied by an additional 10 for individual differences in the general human population, the uncertainty factor of the NOAEL human_env in the general environment is found to be 90. À2 mg/m 3 and 2.7 3 10 À4 mg/m 3 , respectively (EC, 2010). The differences between these values may have two causes. The first is a difference in the concept of adverse effect. In determining the DNEL, the researchers used the expression levels of three kinds of gene associated with inflammation to indicate an adverse effect. In contrast, we did not use gene expression as an indicator of an adverse effect because gene expression does not directly indicate the adverse effect. Instead, we used the increase of neutrophils in the BALF and the direct observation of alveolar inflammation as indicators of adverse effects. In addition, different uncertainty factors were used in the two studies. The uncertainty factors used by ENRHES were interspecies variation (2.5), intraspecies variation (5), and extrapolation from a subacute to a chronic effect (6), whereas our assessment used the uncertainty factors of interspecies variation (1), intraspecies variation (1 or 10), interspecies conversion of NOAEL (3), and extrapolation from an intratracheal instillation test to a subchronic effect (3).
Discussion of particle size and surface area. Although the relationship between particle size and hazard strength has not been fully elucidated, nanoparticles are possible to retain in lung longer (TiO 2 : Ferin et al., 1992) and easier induce inflammation/oxidation stresses (carbon black: Gilmour et al., 2004; Li et al., 1999 ) than micron-sized particle. With regard to fullerene, the adverse effects of nanosized C 60 particles were reported to be equivalent to micron-sized C 60 particles (inhalation rat study : Baker et al., 2008) or stronger (antibacterial activity: Lyon et al., 2006) than micron-sized C 60 particles. The hazard strength associated with particle size could depend on two factors: (1) the difference in the rate of deposition in the pulmonary alveolus for different secondary-particle sizes and (2) the possible difference in hazard strength per unit weight for different primary-particle sizes. In other words, the latter suggested that particle surface area is the relevant index of exposure, contributing to adverse effects (Donaldson et al., 2001; Oberdörster, 2000; Oberdörster et al., 2005) The toxicity, associated with particle size and surface area, considered in this study can be explained as follows. There are two general classifications of submicron/micron-sized particles (Fig. 4) : (a) aggregates/agglomerates of nanosized particles and (b) a single particle of submicron/micron size. For the particles classified as a, where the surface area is equivalent to that of a nanosized particle and the hazard strength is equivalent to that of a nanosized particle, only the difference in the rate of deposition in the pulmonary alveolus should be considered, even if hazard strength depends on surface area. By contrast, for those particles classified as b, only the differences in rate of deposition in the pulmonary alveolus should be considered if hazard strength depends on particle weight; however, if hazard strength also depends on surface area, their hazard strength per weight would be smaller than that of nanosized particles. Therefore, when applying the estimated in the present assessment to those particles classified under b, the estimated AEL(PL) are conservative estimates even considering the differences in rates of deposition in the pulmonary alveolus. In this assessment, the particles in Morimoto et al (2010) and Sayes et al (2007) were equivalent to the particles classified as a. Although the assessed risks are not conservative estimates if the primary particle size in the workplace is smaller than that in Morimoto et al (2010) and Sayes et al (2007) , the primary particle sizes in the workplace as seen in previous reports have been larger than that those of Morimoto et al (2010) and Sayes et al (2007) .
It may become possible to establish a separate AEL(PL) for micron-sized fullerene particles once sufficient data have been generated to evaluate the hazard strength of the particles classified under category b.
CONCLUSIONS
Fullerene C 60 is a candidate substance in many nanotechnology applications in the industrial and medical fields. Meanwhile, the safety of C 60 is a subject of worldwide concern due to the lack of the hazard information. Therefore, we reviewed the toxicity information of C 60 on the lungs as a hazard assessment. The NOAEL of C 60 (GM of 96 nm and GSD of 2.0) on rat lung toxicity was estimated to be 3.1 mg/m 
